Navigation Links
New Treatment Option For Alzheimer's Disease

Alzheimer's disease is the most common form of dementia in the elderly with typical symptoms being memory loss, speech deterioration, and // behavioral changes. An early study of the drug rolipram in mice shows promise for possible use in treating Alzheimer's disease in people, according to a new study.

Researchers say they found that treatment of a mouse form of AD with rolipram improves memory in long-term potential and contextual learning -- two measurements of brain function.According to researchers Rolipram works by modifying gene expression, making brain synapses more resistant to the damage caused by accumulating beta amyloid.

Results showed rolipram's protective benefit lasted at least two months after the drug course was stopped. The benefits of the treatment also were not limited to the early stages of AD, with behavioral changes occurring in older mice as well as younger mice.

Thus in conclusion researchers suggest that drugs, such as rolipram, that inhibit phosphodiesterase have the potential to prevent the memory loss characteristic of Alzheimer's disease.
'"/>




Page: 1

Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis

Post Your Comments:
(Date:11/7/2009)... October 23-25th marked the ...nd celebrities fighting the battle against pediatr...he foundation and it,s efforts for many years. , ...s) November 7, 2009 -- The weekend of October 23-2...ther anglers and celebrities fighting the battle a...
(Date:11/6/2009)...LANTA, Nov. 6 Recently a Narconon of Georgia grad...xperience with prescription drug abuse. The specia...ption drug addiction . In the report Andrew sh... more should be done to prevent prescription drug ...ing I knew I opened my eyes to my father on top of...
(Date:11/6/2009)...OTTSDALE, Ariz., Nov. 6 Healthcare Trust of Ameri... real estate investment trust, announced the execu...ent") to acquire a medical office building located...000. ,, The Hampden Place Medical Center is locat...ented, mixed-use redevelopment district. Hampden P...
(Date:11/6/2009)...KE FOREST, Ill., Nov. 6 Hospira, Inc. (NYSE: HSP...medication delivery company, today announced that ... Annual Health Care Conference on Wednesday, Dec. ...cheduled to begin at 9:30 a.m. Eastern time on Wed... interested parties through a live audiocast acces...
(Date:11/6/2009)...t-term limitations seem to wane as years go by, re...y News) -- New research suggests that people with ...ears of developing the disease are more likely to ...han others with the condition. , The findings, pub...h the disease who relapse within five years of dev...
Breaking Medicine News(10 mins):Health News:Updegraff Vision Proudly Supports The Pediatric Cancer Foundation 2Health News:Updegraff Vision Proudly Supports The Pediatric Cancer Foundation 3Health News:Narconon Drug Rehab of Georgia Graduate Featured on Local News 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 66,339 SF Medical Office Building Located in Englewood, Colorado 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 66,339 SF Medical Office Building Located in Englewood, Colorado 3Health News:Early Relapse of MS May Mean Fewer Issues Later 2
...urth Annual Physician On-Call Pay ...n, Cotter and Associates, Inc.,has published its f... and,practices, the 2008 Physician On-call Pay Sur...hysician specialty areas along,with data reported ...
...egins -, CORONA, Calif., July 25 Watson,Pharmace...harmaceutical,company, announced today that its su...Omeprazole Delayed-Release Capsules USP product in...ing the,first to file an ANDA containing a paragra...
..., Robert J. Reilly, Joins Aethon Team, PITTSBURGH...the leading developer of mobile robotics for,hospi...obert J. Reilly has,joined the company as Senior V...acy Division, brings more than 30,years of experie...
...f Companies will,showcase their unique line of can...iation of Physicists in Medicine (AAPM) annual mee... IMPAC and CMS are delivering,cutting-edge radiati...ian efficiency., "Our recent acquisition of CMS b...
...cs, Inc. today,announced that it has filed a regis...and Exchange Commission relating to the proposed i...ck. The number of shares of common,stock to be off... Securities Inc. is acting as sole book-running ma...
...ying to drop pounds, study finds , , FRIDA...ded Monday morning weigh-ins knows this unalterabl..., researchers have some science to back up dieters...es can wreak havoc on weight control, either causi...
Other Medicine News:Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:Weekends Tough on the Diet 2Health News:Weekends Tough on the Diet 3
(Date:11/6/2009)..., BOTHELL, Wash., Nov. 6 ...inancial results for the three and nine months end...SCOLR Pharma,s President and CEO, said, "We contin... 12-hour ibuprofen formulation. Several potential ...ime, personnel and external resources as they eval...
(Date:11/6/2009)..., SAN DIEGO, Nov. 6 Trius Therapeu...istration statement on Form S-1 with the U.S. Secu... proposed initial public offering of shares of its...e sold in the offering will be offered by the Comp...cting as sole book-running manager, Piper Jaffray ...
(Date:11/6/2009)..., DETROIT, Nov. 6 Caraco...D ) has launched ketorolac tromethamine ophthalmic...e US Food and Drug Administration (FDA) for Sun Ph... generic Acular® ophthalmic solution on the f...h of ketorolac is therapeutically equivalent to Ac...
Breaking Medicine Technology:SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 8SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 9Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution 2LCA Applauds Senate Leadership Team Working to Secure New FDA Regulatory Authority Over Tobacco 47852 1LCA Applauds Senate Leadership Team Working to Secure New FDA Regulatory Authority Over Tobacco 47852 2U S Civil Rights Commission to Hold Public Briefing on Health Care Disparities Between Minorities and Non Minorities and Business Meeting 47848 1U S Civil Rights Commission to Hold Public Briefing on Health Care Disparities Between Minorities and Non Minorities and Business Meeting 47848 2U S Civil Rights Commission to Hold Public Briefing on Health Care Disparities Between Minorities and Non Minorities and Business Meeting 47848 3InterMune to Present at Goldman Sachs Healthcare Conference 12456 1
...BUSINESS WIRE)-May 10, 2007--Today, the,New Englan...wo,Phase III studies of Merck,s cervical cancer va... (Types 6, 11, 16, 18),Recombinant Vaccine). In th...ction against cervical, vaginal and vulvar disease...d to protect,against, HPV types 6, 11, 16, and 18....
...May 11, 2007 /PRNewswire-FirstCall/ --,NicOx S.A. ...ase 2a,study for NCX 1000, which is covered by its... preliminary analysis of 11 patients,from this pro...ed,the safety profile of NCX 1000 but did not demo...nuation of this clinical trial. As a,consequence, ...
Other Medicine Technology:New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 2New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 3New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 4New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 5New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 6New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 7New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 8New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 9New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 10New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 11New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 12New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 13New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 14New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 15New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 16New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 17New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 18New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 19New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 20New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 21New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 22New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 23New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 24New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 25New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 26New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 27New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 28New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 29New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 30New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 31New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 32NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 2NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 3
Lacoste Sun Collection
Bvlgari Vision Collection
Aristar Eyewear Collection
...r and style. Creativity and cutting-edge design. D...ompanies, signed a new licensing agreement in Octo...985 by the famous designer duo, Domenico Dolce and...r Mediterranean roots to create the distinguishing...
Medicine Products: